Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Assets
Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) holds total assets worth CN¥10.69 Billion CNY (≈ $1.56 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Nanjing King-friend Biochemical Pharmace to assess the company's total reinvestment commitment from operating cash flow.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Nanjing King-friend Biochemical Pharmace (603707) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets of CN¥10.69 Billion consist of 72.7% current assets and 27.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.5% |
| Accounts Receivable | CN¥1.22 Billion | 11.8% |
| Inventory | CN¥3.26 Billion | 31.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.18 Billion | 11.5% |
| Goodwill | CN¥126.64 Million | 1.2% |
Asset Composition Trend (2013–2025)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanjing King-friend Biochemical Pharmace stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's current assets represent 72.7% of total assets in 2025, a decrease from 73.8% in 2013.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 26.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 31.6% of total assets.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
Canada | CA$24.50 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
China Animal Husbandry Industry Co Ltd
SHG:600195
|
China | CN¥9.32 Billion |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 4.55 | 2.29 |
| Quick Ratio | 1.40 | 2.09 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.42 Billion | CN¥4.89 Billion | CN¥4.31 Billion |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | CN¥10.34 Billion |
| Market Capitalization | $1.69 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total assets of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.34 Billion ≈ $1.51 Billion |
+8.75% |
| 2024-12-31 | CN¥9.51 Billion ≈ $1.39 Billion |
-0.15% |
| 2023-12-31 | CN¥9.52 Billion ≈ $1.39 Billion |
-4.85% |
| 2022-12-31 | CN¥10.01 Billion ≈ $1.46 Billion |
+21.82% |
| 2021-12-31 | CN¥8.22 Billion ≈ $1.20 Billion |
+6.43% |
| 2020-12-31 | CN¥7.72 Billion ≈ $1.13 Billion |
+52.02% |
| 2019-12-31 | CN¥5.08 Billion ≈ $743.13 Million |
+49.26% |
| 2018-12-31 | CN¥3.40 Billion ≈ $497.87 Million |
+26.26% |
| 2017-12-31 | CN¥2.69 Billion ≈ $394.33 Million |
+76.97% |
| 2016-12-31 | CN¥1.52 Billion ≈ $222.82 Million |
+17.37% |
| 2015-12-31 | CN¥1.30 Billion ≈ $189.85 Million |
-15.76% |
| 2014-12-31 | CN¥1.54 Billion ≈ $225.37 Million |
+33.08% |
| 2013-12-31 | CN¥1.16 Billion ≈ $169.34 Million |
-- |
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more